What’s Inside

Working with our partners at Sermo, this report leverages Talking Medicines Drug-GPT and Sermo’s Brand Pulse. We set out to better understand current challenges as well as perceptions, attitudes, and  usage around GLP-1 and GIP/GIP-1 medications among patients and physicians.

Download this exclusive report to:

• Gain insight into how GLP-1 and GIP/GLP-1 drugs have revolutionized the type 2 diabetes space.
• Explore how physicians and patients alike are talking, thinking, and reacting to GLP-1 and GIP/GLP-1 medications.
• Deep dive into learnings about specific medications like semaglutide and tirzepatide both from the physician and patient perspective.